Literature DB >> 33813687

Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC).

Christine Song1, Val J Lowe2, SeungBaek Lee3,4.   

Abstract

BACKGROUND: Cdc20 is a crucial activator of the anaphase-promoting complex (APC/C) and is known to be essential in mitosis regulation. Abnormally high expression of Cdc20 has been reported in several malignancies. We aimed to study the Cdc20 expression in human breast cancer tissues, focusing specifically on Cdc20 in Triple-Negative Breast Cancer (TNBC).
METHODS: The expression of mitotic regulators mRNA in three TNBC cell lines or three other breast cancer cell lines was determined by the RNA-sequencing database. 14,713 human breast cancer patient samples included in Breast Cancer-GenExminer v4.5 were used to analyze whether cell division cycle 20 (Cdc20) expression was related to TNBC. To find whether Cdc20 expression impacted prognosis in TNBC, we used 2,249 TNBC patients database. The loss of Cdc20 by RNA interference (shRNA) and several mitotic inhibitors including Apcin, ZM447439, BI 2536, and VX-680 on the capacities of proliferation, migration, invasion were evaluated by colony-forming, wound-healing, transwell assay, and western blot, respectively.
RESULTS: We studied the mitosis-related genes and proteins that are closely related to TNBC through the National Center for Biotechnology Information (NCBI) database. We found that Cdc20, one of the central mitotic regulators, is significantly upregulated in human TNBC, and its expression level is positively correlated with metastasis-free and relapse-free patient survival. We also found Cdc20 is highly conserved in TNBC in comparison to other breast cancer subtype cell lines. Cdc20 deficiency results in a decrease in cell growth and migration in four TNBC cell lines. Also, several mitotic inhibitors, such as Apcin, VX-680, ZM447439, and BI 2536, blocked cancer cell growth and invasion.
CONCLUSIONS: These results suggest an essential role of Cdc20 in tumor formation and metastasis of TNBC, which might be a potential target therapy for TNBC treatment.
© 2021. The Japanese Breast Cancer Society.

Entities:  

Keywords:  Cell division cycle 20 (Cdc20),; Metastasis,; Mitotic inhibitors; Proliferation,; Triple-negative breast cancer (TNBC),

Mesh:

Substances:

Year:  2021        PMID: 33813687     DOI: 10.1007/s12282-021-01242-z

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  50 in total

1.  Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes.

Authors:  Elaine M Walsh; Maccon M Keane; David A Wink; Grace Callagy; Sharon A Glynn
Journal:  Crit Rev Oncog       Date:  2016

2.  Manipulation as the primary treatment of the frozen shoulder.

Authors:  J F Haines; E J Hargadon
Journal:  J R Coll Surg Edinb       Date:  1982-09

3.  Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.

Authors:  Chi Peng Timothy Lai; Joe Poh Sheng Yeong; An Sen Tan; Chong Hui Clara Ong; Bernett Lee; Jeffrey Chun Tatt Lim; Aye Aye Thike; Jabed Iqbal; Rebecca Alexandra Dent; Elaine Hsuen Lim; Puay Hoon Tan
Journal:  Breast Cancer Res Treat       Date:  2019-08-13       Impact factor: 4.872

4.  Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer.

Authors:  Jie Xu; Xing Wu; Wei-hua Zhou; An-wen Liu; Jian-bing Wu; Jin-yun Deng; Cai-feng Yue; Shao-bing Yang; Jing Wang; Zhong-yu Yuan; Quentin Liu
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

Review 5.  Cdc20: a WD40 activator for a cell cycle degradation machine.

Authors:  Hongtao Yu
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

6.  Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.

Authors:  Carol A Parise; Vincent Caggiano
Journal:  J Cancer Epidemiol       Date:  2014-05-26

7.  Loss of PICH promotes chromosome instability and cell death in triple-negative breast cancer.

Authors:  Yan Huang; Wanjin Li; Weiwei Yan; Jiaqi Wu; Liang Chen; Xiaohong Yao; Feng Gu; Luye Lv; Jiangman Zhao; Ming Zhao; Tian Xia; Qiuying Han; Teng Li; Xiaomin Ying; Tao Li; Qing Xia; Ailing Li; Xuemin Zhang; Yuan Chen; Tao Zhou
Journal:  Cell Death Dis       Date:  2019-06-03       Impact factor: 8.469

Review 8.  Recent advances in triple negative breast cancer: the immunotherapy era.

Authors:  Antonio Marra; Giulia Viale; Giuseppe Curigliano
Journal:  BMC Med       Date:  2019-05-09       Impact factor: 8.775

Review 9.  Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping.

Authors:  Xiaofeng Dai; Hongye Cheng; Zhonghu Bai; Jia Li
Journal:  J Cancer       Date:  2017-09-12       Impact factor: 4.207

Review 10.  Triple-negative breast cancer molecular subtyping and treatment progress.

Authors:  Li Yin; Jiang-Jie Duan; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Breast Cancer Res       Date:  2020-06-09       Impact factor: 6.466

View more
  6 in total

1.  Design, Synthesis, and Biological Evaluation of Apcin-Based CDC20 Inhibitors.

Authors:  Rajib Bhuniya; Xinrui Yuan; Longchuan Bai; Kathryn L Howie; Rui Wang; Wei Li; Frank Park; Chao-Yie Yang
Journal:  ACS Med Chem Lett       Date:  2022-01-18       Impact factor: 4.345

2.  Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis.

Authors:  Wenting Chen; Dan Liu; Guyun Wang; Yanping Pan; Shuwen Wang; Ruimei Tang
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

3.  Selected ideal natural ligand against TNBC by inhibiting CDC20, using bioinformatics and molecular biology.

Authors:  Naimeng Liu; Xinhui Wang; Zhu Zhu; Duo Li; Xiaye Lv; Yichang Chen; Haoqun Xie; Zhen Guo; Dong Song
Journal:  Aging (Albany NY)       Date:  2021-10-22       Impact factor: 5.682

4.  Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.

Authors:  Yiming Ding; Chuanbao Zhang; Lei He; Xinyu Song; Chengjun Zheng; Yuchu Pan; Shuqing Yu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic.

Authors:  Yuewen Zhang; Lei Wu; Zhao Wang; Jinpeng Wang; Shrabasti Roychoudhury; Bartlomiej Tomasik; Gang Wu; Geng Wang; Xinrui Rao; Rui Zhou
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

6.  Identification of a novel ubiquitination related gene signature for patients with breast cancer.

Authors:  Yuan Zheng; Wenliang Lu; Bo Chen; Kankan Zhao
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.